SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS

SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS

The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer. La pré...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CLAYTON, Joshua Ryan, JOHNSTON, Richard Duane, LAMAR, Jason Eric, FURNESS, Kelly Wayne, RUBIO, Almudena, ZHAO, Gaiying, BARDA, David Anthony, FRANCISKOVICH, Jeffry Bernard, GERNERT, Douglas Linn, ZIA-EBRAHIMI, Mohammed Sadegh, SI, Chong, JONES, Spencer Brian, MBOFANA, Curren Tapfuma, HENRY, James Robert, RODRIGUEZ, Michael John, LEVINSON, Adam Marc
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer. La présente invention concerne des composés de formule : dans laquelle R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y et Z sont tels que décrits dans la description, des sels pharmaceutiquement acceptables de ceux-ci, ainsi quedes procédés d'utilisation de ces composés et de leurs sels pharmaceutiquement acceptables pour traiter des patients atteints d'un cancer.